查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1454048

2030 年慢性咳嗽市场预测：按药物类别、给药途径、分销管道、最终用户和地区进行的全球分析

Chronic Cough Market Forecasts to 2030 - Global Analysis By Drug Class, Route of Administration, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球慢性咳嗽市场规模为 73 亿美元，预计在预测期内将以 10.0% 的复合年增长率增长，到 2030 年达到 143 亿美元。

根据大多数医学定义，慢性咳嗽是指成人持续超过 8 週、儿童持续超过 4 週的持续性咳嗽。慢性咳嗽是一种症状，而不是一种疾病，可能由多种潜在疾病引起，包括气喘、过敏、胃食道逆流 (GERD)、流鼻涕、吸烟、慢性支气管炎和某些药物。慢性咳嗽会对生活品质产生重大影响，可能需要进行医学评估以确定根本原因和适当的治疗。

印度 2017 年国家卫生政策旨在 2025 年将慢性咳嗽等非传染性疾病造成的过早死亡率降低 25%。

慢性呼吸道疾病增加

市面上慢性呼吸道疾病的盛行率显着上升。这种快速增长是由多种因素造成的，包括环境污染、生活方式的改变和人口老化。慢性呼吸道疾病越来越普遍，促进了市场的扩大。随着人们所认识的提高和诊断技术的进步，对慢性呼吸道疾病有效治疗方法的需求不断增加，推动了该领域的进一步成长。

副作用和安全问题

慢性咳嗽药物的常见副作用包括嗜睡、头晕和胃肠道不适。潜在的药物交互作用以及依赖和滥用某些药物的风险也存在安全性问题。患有心血管或呼吸系统疾病等潜在疾病的患者的风险可能会增加。医疗保健提供者必须仔细评估每位患者的病历并密切监测治疗结果，以减轻这些担忧。因此，这些都是限制市场成长的因素。

医疗保健支出增加

由于多种因素，包括诊断率的提高、患者数量的增加以及治疗方法的进步，市场的医疗保健支出正在显着增长。随着意识的提高和更多患者寻求慢性咳嗽的治疗，医疗费用继续稳定增加。这一趋势凸显了将解决慢性咳嗽作为医疗保健优先事项的重要性，并强调需要继续投资该细分市场的研发和患者照护工作。

昂贵的治疗费用

慢性咳嗽市场正在应对治疗成本上升的重大挑战，对患者和医疗保健系统造成沉重负担。与治疗和持续管理相关的费用增加了寻求缓解这种持续性疾病的患者的经济负担。儘管医疗技术和治疗方法取得了进步，但高昂的治疗成本仍然是许多患者的治疗障碍，迫切需要负担得起且永续的医疗保健解决方案。

COVID-19 的影响：

COVID-19 大流行严重影响了慢性咳嗽市场，扰乱了诊断、治疗和患者照护。封锁措施、获得医疗保健的机会减少以及优先分配资源来管理 COVID-19 导致慢性咳嗽的管理延误。此外，由于害怕去医疗机构就诊，患者不敢及时寻求治疗。结果，诊断率和治疗开始率下降，影响了市场成长。远端医疗已成为首选的咨询方法，在一定程度上缓解了限制，但它还无法完全取代现场评估。

减充血剂领域预计将成为预测期内最大的市场

由于人们对呼吸系统疾病的认识和盛行率不断提高，鼻减充血剂市场预计在预测期内将成为最大的市场。它可以缓解鼻塞和鼻后流鼻涕，并解决持续咳嗽的根本原因。製药公司正在积极从事研究和开发，以增强现有配方并推出新的鼻减充血剂。这种动态的市场情况证明了有效的减充血剂在治疗慢性咳嗽和相关呼吸道疾病中的重要性。

预计医院业在预测期内复合年增长率最高。

预计医院业在预测期内复合年增长率最高。专门从事呼吸系统健康的大型医院，包括着名的学术医疗中心和呼吸系统医疗设备，是主要参与者。这些医院提供全面的服务，包括诊断影像、肺功能测试以及多学科专家团队的服务。此外，我们提供尖端的治疗方法和临床试验，以确保患者的慢性咳嗽症状得到最佳的护理和管理。

比最大的地区

预计北美在预测期内将占据最大的市场占有率。药物疗法，包括镇咳药和标靶治疗，占据市场主导地位。此外，针对新治疗方法的研发活动的迅速增加进一步支持了市场扩张。市场以改善患者治疗效果和生活品质为重点，不断发展，并带来充满希望的创新和投资机会。

复合年增长率最高的地区：

由于污染水平上升、老年人口增加、生活方式改变导致呼吸系统疾病盛行率上升，以及对可用治疗方案的认识不断增强，预计亚太地区将在预测期内保持最高的复合年增长率。此外，人们对言语治疗、呼吸练习和生活方式改变等非药物干预措施越来越感兴趣。该地区各国的市场法律规范各不相同，影响着市场动态和产品供应。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球慢性咳嗽市场：依药物类别

  • 抗生素
  • 酸阻断剂
  • 皮质类固醇
  • 鼻减充血剂
  • 组合药物
  • 抗组织胺药
  • 其他药物类别

第六章全球慢性咳嗽市场：依给药途径分类

  • 吸入
  • 口服
  • 注射
  • 其他给药途径

第七章全球慢性咳嗽市场：按分销管道

  • 零售药房
  • 医院药房
  • 网路药房

第八章全球慢性咳嗽市场：依最终用户分类

  • 专业中心
  • 居家照护
  • 医院
  • 其他最终用户

第九章全球慢性咳嗽市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第10章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司简介

  • Teva Pharmaceuticals Industries
  • Mylan NV
  • Amneal Pharmaceuticals LLC
  • Novartis AG
  • Hikma Pharmaceuticals Plc
  • Bayer AG
  • GSK plc
  • Aurobindo Pharma
  • Apotex Inc.
  • Micro Labs Ltd
  • AstraZeneca plc
  • Sun Pharmaceuticals Industries Ltd
  • Cipla Limited
  • Glenmark Pharmaceuticals Ltd
  • NeRRe Therapeutics
  • Pfizer Inc.
Product Code: SMRC25600

According to Stratistics MRC, the Global Chronic Cough Market is accounted for $7.3 billion in 2023 and is expected to reach $14.3 billion by 2030 growing at a CAGR of 10.0% during the forecast period. A chronic cough is a persistent cough that lasts for more than eight weeks in adults or four weeks in children, according to most medical definitions. It's a symptom rather than a disease itself and can be caused by a variety of underlying conditions such as asthma, allergies, gastroesophageal reflux disease (GERD), postnasal drip, smoking, chronic bronchitis, or certain medications. Chronic cough can significantly impact quality of life and may require medical evaluation to determine the underlying cause and appropriate treatment.

According to the National Health Policy 2017, India, premature mortality due to non-communicable diseases, including chronic cough, will be reduced by ~ 25% by 2025.

Market Dynamics:

Driver:

Increasing prevalence of chronic respiratory diseases

The market is witnessing a notable rise in chronic respiratory diseases prevalence. This surge is attributed to various factors such as environmental pollution, lifestyle changes, and aging populations. Chronic respiratory conditions are increasingly prevalent, contributing to the expansion of the market. With growing awareness and diagnostic advancements, the demand for effective treatments for chronic respiratory ailments continues to escalate, driving further growth in this sector.

Restraint:

Side effects and safety concerns

Common side effects of pharmaceutical treatments for chronic cough include drowsiness, dizziness, and gastrointestinal disturbances. There are safety concerns regarding potential drug interactions and the risk of dependency or abuse with certain medications. Patients with underlying medical conditions such as cardiovascular issues or respiratory disorders may face heightened risks. It's imperative for healthcare providers to carefully assess each patient's medical history and closely monitor treatment outcomes to mitigate these concerns. Hence, these are the factors impeding the growth of the market.

Opportunity:

Rising healthcare expenditure

The market is witnessing a notable surge in healthcare expenditure, driven by various factors such as increased diagnosis rates, expanding patient populations, and advancements in treatment options. As awareness grows and more patients seek medical attention for chronic cough, healthcare spending continues to rise steadily. This trend underscores the significance of addressing chronic cough as a healthcare priority and highlights the need for continued investment in research, development, and patient care initiatives within this market segment.

Threat:

High cost of treatment

The market grapples with the significant challenge of high treatment costs, posing a considerable burden on patients and healthcare systems alike. The expenses associated with therapies and ongoing management contribute to financial strain for individuals seeking relief from this persistent condition. Despite advancements in medical technology and treatment modalities, the steep costs remain a barrier to access for many, underscoring the pressing need for affordable and sustainable solutions within the healthcare landscape.

Covid-19 Impact:

The COVID-19 pandemic significantly affected the Chronic Cough market, causing disruptions in diagnosis, treatment, and patient care. Lockdown measures, reduced healthcare access, and prioritization of resources towards managing COVID-19 led to delays in chronic cough management. Additionally, fear of visiting healthcare facilities deterred patients from seeking timely treatment. Consequently, there was a decline in diagnosis rates and treatment initiation, impacting market growth. Telemedicine emerged as a preferred mode for consultation, offering some relief amidst restrictions but couldn't fully compensate for in-person evaluations.

The decongestants segment is expected to be the largest during the forecast period

The decongestants segment is expected to be the largest during the forecast period driven by increasing awareness and prevalence of respiratory conditions. They alleviate nasal congestion and postnasal drip, addressing underlying causes of persistent coughing. Pharmaceutical companies actively engage in research and development to enhance existing formulations and introduce novel decongestant products. This dynamic market landscape underscores the importance of effective decongestants in managing chronic cough and related respiratory ailments.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is expected to have the highest CAGR during the forecast period. Leading hospitals specializing in respiratory health, such as renowned academic medical centers and pulmonology departments, are crucial players. These hospitals offer comprehensive services, including diagnostic imaging, pulmonary function testing, and access to multidisciplinary teams of specialists. Additionally, they provide cutting-edge therapies and clinical trials, ensuring patients receive optimal care and management for their chronic cough conditions.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. Pharmaceutical interventions, including antitussive medications and targeted therapies, dominate the market landscape. Additionally, a surge in research and development activities aimed at novel treatment modalities further propels market expansion. With a focus on improving patient outcomes and quality of life, the market continues to evolve with promising opportunities for innovation and investment.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period owing to increasing pollution levels, rising geriatric population, changing lifestyles leading to higher incidence of respiratory diseases, and growing awareness about available treatment options. Additionally, there was growing interest in non-pharmacological interventions such as speech therapy, breathing exercises, and lifestyle modifications. Regulatory frameworks governing the market varied across countries in the region, influencing market dynamics and product availability.

Key players in the market

Some of the key players in Chronic Cough market include Teva Pharmaceuticals Industries, Mylan N.V., Amneal Pharmaceuticals LLC, Novartis AG, Hikma Pharmaceuticals Plc, Bayer AG, GSK plc, Aurobindo Pharma, Apotex Inc., Micro Labs Ltd, AstraZeneca plc, Sun Pharmaceuticals Industries Ltd, Cipla Limited, Glenmark Pharmaceuticals Ltd, NeRRe Therapeutics and Pfizer Inc.

Key Developments:

In September 2022, Pfizer Inc., a US-based biopharmaceutical company, acquired ASX-listed digital health startup ResApp Health for $115 million. With this acquisition, Pfizer aimed to enhance its product portfolio and expand its presence in crucial healthcare technology areas.

In January 2022, Merck announced Gefapixant, a non-narcotic, oral selective P2X3 receptor antagonist for the treatment of patients with RCC or unexplained chronic cough (UCC), was approved by FDA.

Drug Classes Covered:

  • Antibiotics
  • Acid Blockers
  • Corticosteroids
  • Decongestants
  • Combination Drug
  • Antihistamines
  • Other Drug Classes

Route of Administrations Covered:

  • Inhalational
  • Oral
  • Injectable
  • Other Route of Administrations

Distribution Channels Covered:

  • Retail Pharmacy
  • Hospital Pharmacy
  • Online Pharmacy

End Users Covered:

  • Speciality Centres
  • Homecare
  • Hospitals
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Chronic Cough Market, By Drug Class

  • 5.1 Introduction
  • 5.2 Antibiotics
  • 5.3 Acid Blockers
  • 5.4 Corticosteroids
  • 5.5 Decongestants
  • 5.6 Combination Drug
  • 5.7 Antihistamines
  • 5.8 Other Drug Classes

6 Global Chronic Cough Market, By Route of Administration

  • 6.1 Introduction
  • 6.2 Inhalational
  • 6.3 Oral
  • 6.4 Injectable
  • 6.5 Other Route of Administrations

7 Global Chronic Cough Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Retail Pharmacy
  • 7.3 Hospital Pharmacy
  • 7.4 Online Pharmacy

8 Global Chronic Cough Market, By End User

  • 8.1 Introduction
  • 8.2 Speciality Centres
  • 8.3 Homecare
  • 8.4 Hospitals
  • 8.5 Other End Users

9 Global Chronic Cough Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Teva Pharmaceuticals Industries
  • 11.2 Mylan N.V.
  • 11.3 Amneal Pharmaceuticals LLC
  • 11.4 Novartis AG
  • 11.5 Hikma Pharmaceuticals Plc
  • 11.6 Bayer AG
  • 11.7 GSK plc
  • 11.8 Aurobindo Pharma
  • 11.9 Apotex Inc.
  • 11.10 Micro Labs Ltd
  • 11.11 AstraZeneca plc
  • 11.12 Sun Pharmaceuticals Industries Ltd
  • 11.13 Cipla Limited
  • 11.14 Glenmark Pharmaceuticals Ltd
  • 11.15 NeRRe Therapeutics
  • 11.16 Pfizer Inc.

List of Tables

  • Table 1 Global Chronic Cough Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Chronic Cough Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 3 Global Chronic Cough Market Outlook, By Antibiotics (2021-2030) ($MN)
  • Table 4 Global Chronic Cough Market Outlook, By Acid Blockers (2021-2030) ($MN)
  • Table 5 Global Chronic Cough Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 6 Global Chronic Cough Market Outlook, By Decongestants (2021-2030) ($MN)
  • Table 7 Global Chronic Cough Market Outlook, By Combination Drug (2021-2030) ($MN)
  • Table 8 Global Chronic Cough Market Outlook, By Antihistamines (2021-2030) ($MN)
  • Table 9 Global Chronic Cough Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 10 Global Chronic Cough Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 11 Global Chronic Cough Market Outlook, By Inhalational (2021-2030) ($MN)
  • Table 12 Global Chronic Cough Market Outlook, By Oral (2021-2030) ($MN)
  • Table 13 Global Chronic Cough Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 14 Global Chronic Cough Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
  • Table 15 Global Chronic Cough Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 16 Global Chronic Cough Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 17 Global Chronic Cough Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 18 Global Chronic Cough Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 19 Global Chronic Cough Market Outlook, By End User (2021-2030) ($MN)
  • Table 20 Global Chronic Cough Market Outlook, By Speciality Centres (2021-2030) ($MN)
  • Table 21 Global Chronic Cough Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 22 Global Chronic Cough Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 23 Global Chronic Cough Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 24 North America Chronic Cough Market Outlook, By Country (2021-2030) ($MN)
  • Table 25 North America Chronic Cough Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 26 North America Chronic Cough Market Outlook, By Antibiotics (2021-2030) ($MN)
  • Table 27 North America Chronic Cough Market Outlook, By Acid Blockers (2021-2030) ($MN)
  • Table 28 North America Chronic Cough Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 29 North America Chronic Cough Market Outlook, By Decongestants (2021-2030) ($MN)
  • Table 30 North America Chronic Cough Market Outlook, By Combination Drug (2021-2030) ($MN)
  • Table 31 North America Chronic Cough Market Outlook, By Antihistamines (2021-2030) ($MN)
  • Table 32 North America Chronic Cough Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 33 North America Chronic Cough Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 34 North America Chronic Cough Market Outlook, By Inhalational (2021-2030) ($MN)
  • Table 35 North America Chronic Cough Market Outlook, By Oral (2021-2030) ($MN)
  • Table 36 North America Chronic Cough Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 37 North America Chronic Cough Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
  • Table 38 North America Chronic Cough Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 39 North America Chronic Cough Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 40 North America Chronic Cough Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 41 North America Chronic Cough Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 42 North America Chronic Cough Market Outlook, By End User (2021-2030) ($MN)
  • Table 43 North America Chronic Cough Market Outlook, By Speciality Centres (2021-2030) ($MN)
  • Table 44 North America Chronic Cough Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 45 North America Chronic Cough Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 46 North America Chronic Cough Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 47 Europe Chronic Cough Market Outlook, By Country (2021-2030) ($MN)
  • Table 48 Europe Chronic Cough Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 49 Europe Chronic Cough Market Outlook, By Antibiotics (2021-2030) ($MN)
  • Table 50 Europe Chronic Cough Market Outlook, By Acid Blockers (2021-2030) ($MN)
  • Table 51 Europe Chronic Cough Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 52 Europe Chronic Cough Market Outlook, By Decongestants (2021-2030) ($MN)
  • Table 53 Europe Chronic Cough Market Outlook, By Combination Drug (2021-2030) ($MN)
  • Table 54 Europe Chronic Cough Market Outlook, By Antihistamines (2021-2030) ($MN)
  • Table 55 Europe Chronic Cough Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 56 Europe Chronic Cough Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 57 Europe Chronic Cough Market Outlook, By Inhalational (2021-2030) ($MN)
  • Table 58 Europe Chronic Cough Market Outlook, By Oral (2021-2030) ($MN)
  • Table 59 Europe Chronic Cough Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 60 Europe Chronic Cough Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
  • Table 61 Europe Chronic Cough Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 62 Europe Chronic Cough Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 63 Europe Chronic Cough Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 64 Europe Chronic Cough Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 65 Europe Chronic Cough Market Outlook, By End User (2021-2030) ($MN)
  • Table 66 Europe Chronic Cough Market Outlook, By Speciality Centres (2021-2030) ($MN)
  • Table 67 Europe Chronic Cough Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 68 Europe Chronic Cough Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 69 Europe Chronic Cough Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 70 Asia Pacific Chronic Cough Market Outlook, By Country (2021-2030) ($MN)
  • Table 71 Asia Pacific Chronic Cough Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 72 Asia Pacific Chronic Cough Market Outlook, By Antibiotics (2021-2030) ($MN)
  • Table 73 Asia Pacific Chronic Cough Market Outlook, By Acid Blockers (2021-2030) ($MN)
  • Table 74 Asia Pacific Chronic Cough Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 75 Asia Pacific Chronic Cough Market Outlook, By Decongestants (2021-2030) ($MN)
  • Table 76 Asia Pacific Chronic Cough Market Outlook, By Combination Drug (2021-2030) ($MN)
  • Table 77 Asia Pacific Chronic Cough Market Outlook, By Antihistamines (2021-2030) ($MN)
  • Table 78 Asia Pacific Chronic Cough Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 79 Asia Pacific Chronic Cough Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 80 Asia Pacific Chronic Cough Market Outlook, By Inhalational (2021-2030) ($MN)
  • Table 81 Asia Pacific Chronic Cough Market Outlook, By Oral (2021-2030) ($MN)
  • Table 82 Asia Pacific Chronic Cough Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 83 Asia Pacific Chronic Cough Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
  • Table 84 Asia Pacific Chronic Cough Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 85 Asia Pacific Chronic Cough Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 86 Asia Pacific Chronic Cough Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 87 Asia Pacific Chronic Cough Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 88 Asia Pacific Chronic Cough Market Outlook, By End User (2021-2030) ($MN)
  • Table 89 Asia Pacific Chronic Cough Market Outlook, By Speciality Centres (2021-2030) ($MN)
  • Table 90 Asia Pacific Chronic Cough Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 91 Asia Pacific Chronic Cough Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 92 Asia Pacific Chronic Cough Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 93 South America Chronic Cough Market Outlook, By Country (2021-2030) ($MN)
  • Table 94 South America Chronic Cough Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 95 South America Chronic Cough Market Outlook, By Antibiotics (2021-2030) ($MN)
  • Table 96 South America Chronic Cough Market Outlook, By Acid Blockers (2021-2030) ($MN)
  • Table 97 South America Chronic Cough Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 98 South America Chronic Cough Market Outlook, By Decongestants (2021-2030) ($MN)
  • Table 99 South America Chronic Cough Market Outlook, By Combination Drug (2021-2030) ($MN)
  • Table 100 South America Chronic Cough Market Outlook, By Antihistamines (2021-2030) ($MN)
  • Table 101 South America Chronic Cough Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 102 South America Chronic Cough Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 103 South America Chronic Cough Market Outlook, By Inhalational (2021-2030) ($MN)
  • Table 104 South America Chronic Cough Market Outlook, By Oral (2021-2030) ($MN)
  • Table 105 South America Chronic Cough Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 106 South America Chronic Cough Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
  • Table 107 South America Chronic Cough Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 108 South America Chronic Cough Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 109 South America Chronic Cough Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 110 South America Chronic Cough Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 111 South America Chronic Cough Market Outlook, By End User (2021-2030) ($MN)
  • Table 112 South America Chronic Cough Market Outlook, By Speciality Centres (2021-2030) ($MN)
  • Table 113 South America Chronic Cough Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 114 South America Chronic Cough Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 115 South America Chronic Cough Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 116 Middle East & Africa Chronic Cough Market Outlook, By Country (2021-2030) ($MN)
  • Table 117 Middle East & Africa Chronic Cough Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 118 Middle East & Africa Chronic Cough Market Outlook, By Antibiotics (2021-2030) ($MN)
  • Table 119 Middle East & Africa Chronic Cough Market Outlook, By Acid Blockers (2021-2030) ($MN)
  • Table 120 Middle East & Africa Chronic Cough Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 121 Middle East & Africa Chronic Cough Market Outlook, By Decongestants (2021-2030) ($MN)
  • Table 122 Middle East & Africa Chronic Cough Market Outlook, By Combination Drug (2021-2030) ($MN)
  • Table 123 Middle East & Africa Chronic Cough Market Outlook, By Antihistamines (2021-2030) ($MN)
  • Table 124 Middle East & Africa Chronic Cough Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 125 Middle East & Africa Chronic Cough Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 126 Middle East & Africa Chronic Cough Market Outlook, By Inhalational (2021-2030) ($MN)
  • Table 127 Middle East & Africa Chronic Cough Market Outlook, By Oral (2021-2030) ($MN)
  • Table 128 Middle East & Africa Chronic Cough Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 129 Middle East & Africa Chronic Cough Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
  • Table 130 Middle East & Africa Chronic Cough Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 131 Middle East & Africa Chronic Cough Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 132 Middle East & Africa Chronic Cough Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 133 Middle East & Africa Chronic Cough Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 134 Middle East & Africa Chronic Cough Market Outlook, By End User (2021-2030) ($MN)
  • Table 135 Middle East & Africa Chronic Cough Market Outlook, By Speciality Centres (2021-2030) ($MN)
  • Table 136 Middle East & Africa Chronic Cough Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 137 Middle East & Africa Chronic Cough Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 138 Middle East & Africa Chronic Cough Market Outlook, By Other End Users (2021-2030) ($MN)